Hyperparathyroidism during growth hormone treatment: a role for puberty?
We describe three adolescent patients on chronic hemodialysis with a pubertal growth spurt who developed severe hyperparathyroidism during recombinant human growth hormone treatment. Parathyroid hormone levels were raised in parallel with the increase in linear growth in all patients. In two patients, hyperparathyroidism was successfully controlled with an increase in calcitriol dosage. In the third patient, growth hormone had to be withdrawn. We discuss the possibility that puberty is a risk factor for the development of hyperparathyroidism during growth hormone therapy.
Picca
S
S
Division of Nephrology and Dialysis, Bambino Gesù Children's Research Hospital, Rome, Italy. picca@opbg.net
Cappa
M
M
Rizzoni
G
G
D000293:Adolescent; D002117:Calcitriol / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000628:therapy; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D016030:Kidney Transplantation; D008297:Male; D007690:Polycystic Kidney Diseases / Q000150:complications / Q000628:therapy; D011627:Puberty / Q000097:blood / Q000502:physiology*; D006435:Renal Dialysis; D012307:Risk Factors
D013006:Growth Hormone; D002117:Calcitriol